Oncology Clinical Trials in Pittsburgh, PA

As of September 2026, 254 paid clinical trials are recruiting for Oncology in Pittsburgh, Pennsylvania. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

255 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Pittsburgh, PA.

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

for Neoplasms

Sites in Pittsburgh +24 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 1 - 39

Code: NCT05999994·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for Platinum-resistant Ovarian Cancer

Drug: Bevacizumab

Sites in Pittsburgh +32 more locations

Sponsor: Genelux Corporation

Sex: Female·Age: 18+

Code: NCT05281471·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

Sites in Pittsburgh, Philadelphia +92 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT06767514·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

Sites in Pittsburgh, Philadelphia +28 more locations

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

Sites in Pittsburgh +92 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

for Gastroesophageal-junction Cancer

Sites in Pittsburgh, Sayre +27 more locations

Sponsor: Shanghai Henlius Biotech

Sex: All·Age: 18+

Code: NCT06532006·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for Breast Cancer

Sites in Pittsburgh, Bethlehem +111 more locations

Sponsor: Agendia

Sex: All·Age: 18+

Code: NCT03053193·Recruiting·Listed Feb 2017

Apply to this trial

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for Breast Cancer

Sites in Pittsburgh, Harrisburg +51 more locations

Sponsor: Exact Sciences Corporation

Sex: All·Age: 18+

Code: NCT06401421·Recruiting·Listed May 2024

Apply to this trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

for GEP-NET

Sites in Pittsburgh +12 more locations

Sponsor: RayzeBio, Inc.

Sex: All·Age: 18+

Code: NCT05477576·Phase 3·Recruiting·Listed Jul 2022

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

Sites in Pittsburgh, York +29 more locations

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

Sites in Pittsburgh, Philadelphia +56 more locations

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

Sites in Pittsburgh, Philadelphia +26 more locations

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

Drug: Giredestrant

Sites in Pittsburgh, Hershey +24 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

for Breast Neoplasms

Sites in Pittsburgh +14 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07114601·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

Sites in Pittsburgh +17 more locations

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

for Ovarian Cancer

Sites in Pittsburgh +16 more locations

Sponsor: Xencor, Inc.

Sex: All·Age: 15+

Code: NCT06276491·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for CLL

Sites in Pittsburgh, York +24 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06846671·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

for Metastatic Solid Tumor

Sites in Pittsburgh +17 more locations

Sponsor: Coherus Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06657144·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

Drug: daraxonrasib

Sites in Pittsburgh +19 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

for Ovarian Cancer

Sites in Pittsburgh +20 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT06787612·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for Solid Tumor

Sites in Pittsburgh +19 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04939610·Phase 1, Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

for Gastric or Gastroesophageal Junction Adenocarcinoma

Sites in Pittsburgh +9 more locations

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05482893·Phase 1, Phase 2·Recruiting·Listed Aug 2022

Apply to this trial

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for Metastatic Melanoma

Drug: Lifileucel

Sites in Pittsburgh +17 more locations

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023

Apply to this trial

Lead-212 PSV359 Therapy for Patients With Solid Tumors

for Pancreatic Ductal Adenocarcinoma

Sites in Pittsburgh +10 more locations

Sponsor: Perspective Therapeutics

Sex: All·Age: 18 - 90

Code: NCT06710756·Phase 1, Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

Sites in Pittsburgh, Philadelphia +21 more locations

Sponsor: Syncromune, Inc.

Sex: Male·Age: 18+

Code: NCT06533644·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

XTX301 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Pittsburgh +9 more locations

Sponsor: Xilio Development, Inc.

Sex: All·Age: 18+

Code: NCT05684965·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

Sites in Pittsburgh, Philadelphia +11 more locations

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

for Prostate Cancer

Sites in Pittsburgh +23 more locations

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05803941·Phase 4·Recruiting·Listed Apr 2023

Apply to this trial

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

for Recurrent Melanoma (Skin)

Drug: Nivolumab

Sites in Pittsburgh, Philadelphia +10 more locations

Sponsor: Perspective Therapeutics

Sex: All·Age: 18 - 90

Code: NCT05655312·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

for Unresectable Melanoma

Drug: IOV-4001

Sites in Pittsburgh +9 more locations

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05361174·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

Sites in Pittsburgh +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

for Urothelial Carcinoma Bladder

Sites in Pittsburgh +11 more locations

Sponsor: Aktis Oncology, Inc.

Sex: All·Age: 18+

Code: NCT07020117·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

for Refractory Cancer

Drug: Nivolumab

Sites in Pittsburgh, Philadelphia +11 more locations

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT03686124·Phase 1, Phase 2·Recruiting·Listed Sep 2018

Apply to this trial

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

for Melanoma

Drug: Cemiplimab

Sites in Pittsburgh +10 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06413680·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

for Advanced Solid Tumors

Sites in Pittsburgh +9 more locations

Sponsor: Teva Branded Pharmaceutical Products R&D LLC

Sex: All·Age: 18+

Code: NCT06480552·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Pittsburgh, Philadelphia +9 more locations

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT06795412·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for Oncology

Sites in Pittsburgh +12 more locations

Sponsor: Nested Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06326411·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

for Hepatocellular Carcinoma

Sites in Pittsburgh, Philadelphia +10 more locations

Sponsor: Replimune, Inc.

Sex: All·Age: 18+

Code: NCT05733598·Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for Endometrial Cancer

Sites in Pittsburgh, Doylestown +16 more locations

Sponsor: Faeth Therapeutics

Sex: Female·Age: 18+

Code: NCT06463028·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

for Ovarian Cancer

Sites in Pittsburgh +12 more locations

Sponsor: Compugen Ltd

Sex: Female·Age: 18+

Code: NCT06888921·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Conditions in Oncology (Pittsburgh, PA)

Solid tumor· 40 Non-small cell lung cancer (NSCLC)· 38 Breast cancer· 31 Cancer (any)· 29 Melanoma· 22 Ovarian cancer· 18 Head and neck cancer· 18 Colorectal cancer· 17 Endometrial cancer· 16 Pancreatic cancer· 15 Prostate cancer· 15 Esophageal cancer· 14 Liver cancer· 12 Acute myeloid leukemia (AML)· 12 Gastric cancer· 8 Kidney cancer· 8 Fallopian tube cancer· 8 Myelodysplastic syndromes (MDS)· 8 Diffuse large B-cell lymphoma (DLBCL)· 7 Lung cancer· 6 Cervical cancer· 6 Multiple myeloma· 6 Chronic lymphocytic leukemia (CLL)· 6 Skin cancer· 6 Triple-negative breast cancer· 5 Biliary tract cancer· 5 Metastatic prostate cancer· 5 Leukemia (other)· 5 Hematologic malignancy· 5 Metastatic breast cancer· 4 Glioblastoma· 4 Glioma· 4 Brain cancer· 4 Sarcoma· 4 Mesothelioma· 4 Bladder cancer· 3 Acute lymphoblastic leukemia· 3 Myelofibrosis· 3 Myeloproliferative neoplasm· 3 Non-Hodgkin lymphoma· 3 Small lymphocytic lymphoma· 3 Neuroblastoma· 3 HER2-positive breast cancer· 2 Colon cancer· 2 Rectal cancer· 2 Gastroesophageal junction cancer· 2 Follicular lymphoma· 2 HER2-negative breast cancer· 1 Small cell lung cancer· 1 Uterine cancer· 1 Gynecologic cancer· 1 Hodgkin lymphoma· 1 Mantle cell lymphoma· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Thyroid cancer· 1 Osteosarcoma· 1 Rhabdomyosarcoma· 1 Neuroendocrine tumors· 1